New depression diagnosis following prescription of codeine, hydrocodone or oxycodone

Jeffrey F. Scherrer, Joanne Salas, Kathleen K. Bucholz, F. David Schneider, Thomas Burroughs, Laurel A. Copeland, Mark D. Sullivan, Patrick J. Lustman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Purpose: Longer duration of prescription opioid use is associated with risk of major depression after controlling for daily morphine equivalent dose and pain. It is not known if risk of depression varies as a function of the type of opioid prescribed. Methods: A retrospective cohort design was used to model onset of new depression diagnosis among 11462 Veterans Health Administration (VA) patients who were prescribed only codeine, only hydrocodone or only oxycodone for >30days. Patients were free of prevalent opioid use and depression at baseline (2000-2001). Follow-up was 2002-2012. Propensity scores and weighting were used to balance covariates across opioid type. Cox-proportional hazard models were computed, using weighted data and additional adjustment for morphine equivalent dose (MED), duration of use, and pain after opioid initiation, to estimate the risk of new depression diagnosis among patients prescribed only codeine, only oxycodone vs. those prescribed only hydrocodone. Results: After controlling for confounding, we observed that patients prescribed codeine, compared to hydrocodone, were significantly more likely to have a new depression diagnosis (HR=1.27; 95%CI: 1.12-1.43). Oxycodone was significantly associated with onset of new depression diagnosis when exposure was modeled as total days exposed in post-hoc analysis, but not when exposure was duration of incident period of use. Conclusions: Although codeine is a less potent opioid, after controlling for MED, chronic use of this agent is associated with nearly a 30% greater risk of depression compared to hydrocodone. Additional research is needed to determine the mechanisms for this association.

Original languageEnglish (US)
Pages (from-to)560-568
Number of pages9
JournalPharmacoepidemiology and Drug Safety
Volume25
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Hydrocodone
Oxycodone
Codeine
Prescriptions
Depression
Opioid Analgesics
Morphine
Veterans Health
Pain
Propensity Score
United States Department of Veterans Affairs
Proportional Hazards Models
Research Design

Keywords

  • Depression
  • Epidemiology
  • Opioids
  • Pharmacoepidemiology
  • Retrospective cohort

ASJC Scopus subject areas

  • Epidemiology
  • Pharmacology (medical)

Cite this

Scherrer, J. F., Salas, J., Bucholz, K. K., Schneider, F. D., Burroughs, T., Copeland, L. A., ... Lustman, P. J. (2016). New depression diagnosis following prescription of codeine, hydrocodone or oxycodone. Pharmacoepidemiology and Drug Safety, 25(5), 560-568. https://doi.org/10.1002/pds.3999

New depression diagnosis following prescription of codeine, hydrocodone or oxycodone. / Scherrer, Jeffrey F.; Salas, Joanne; Bucholz, Kathleen K.; Schneider, F. David; Burroughs, Thomas; Copeland, Laurel A.; Sullivan, Mark D.; Lustman, Patrick J.

In: Pharmacoepidemiology and Drug Safety, Vol. 25, No. 5, 01.05.2016, p. 560-568.

Research output: Contribution to journalArticle

Scherrer, JF, Salas, J, Bucholz, KK, Schneider, FD, Burroughs, T, Copeland, LA, Sullivan, MD & Lustman, PJ 2016, 'New depression diagnosis following prescription of codeine, hydrocodone or oxycodone', Pharmacoepidemiology and Drug Safety, vol. 25, no. 5, pp. 560-568. https://doi.org/10.1002/pds.3999
Scherrer, Jeffrey F. ; Salas, Joanne ; Bucholz, Kathleen K. ; Schneider, F. David ; Burroughs, Thomas ; Copeland, Laurel A. ; Sullivan, Mark D. ; Lustman, Patrick J. / New depression diagnosis following prescription of codeine, hydrocodone or oxycodone. In: Pharmacoepidemiology and Drug Safety. 2016 ; Vol. 25, No. 5. pp. 560-568.
@article{20cf1ebb2bcc455092c89229e9123c3d,
title = "New depression diagnosis following prescription of codeine, hydrocodone or oxycodone",
abstract = "Purpose: Longer duration of prescription opioid use is associated with risk of major depression after controlling for daily morphine equivalent dose and pain. It is not known if risk of depression varies as a function of the type of opioid prescribed. Methods: A retrospective cohort design was used to model onset of new depression diagnosis among 11462 Veterans Health Administration (VA) patients who were prescribed only codeine, only hydrocodone or only oxycodone for >30days. Patients were free of prevalent opioid use and depression at baseline (2000-2001). Follow-up was 2002-2012. Propensity scores and weighting were used to balance covariates across opioid type. Cox-proportional hazard models were computed, using weighted data and additional adjustment for morphine equivalent dose (MED), duration of use, and pain after opioid initiation, to estimate the risk of new depression diagnosis among patients prescribed only codeine, only oxycodone vs. those prescribed only hydrocodone. Results: After controlling for confounding, we observed that patients prescribed codeine, compared to hydrocodone, were significantly more likely to have a new depression diagnosis (HR=1.27; 95{\%}CI: 1.12-1.43). Oxycodone was significantly associated with onset of new depression diagnosis when exposure was modeled as total days exposed in post-hoc analysis, but not when exposure was duration of incident period of use. Conclusions: Although codeine is a less potent opioid, after controlling for MED, chronic use of this agent is associated with nearly a 30{\%} greater risk of depression compared to hydrocodone. Additional research is needed to determine the mechanisms for this association.",
keywords = "Depression, Epidemiology, Opioids, Pharmacoepidemiology, Retrospective cohort",
author = "Scherrer, {Jeffrey F.} and Joanne Salas and Bucholz, {Kathleen K.} and Schneider, {F. David} and Thomas Burroughs and Copeland, {Laurel A.} and Sullivan, {Mark D.} and Lustman, {Patrick J.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1002/pds.3999",
language = "English (US)",
volume = "25",
pages = "560--568",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - New depression diagnosis following prescription of codeine, hydrocodone or oxycodone

AU - Scherrer, Jeffrey F.

AU - Salas, Joanne

AU - Bucholz, Kathleen K.

AU - Schneider, F. David

AU - Burroughs, Thomas

AU - Copeland, Laurel A.

AU - Sullivan, Mark D.

AU - Lustman, Patrick J.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Purpose: Longer duration of prescription opioid use is associated with risk of major depression after controlling for daily morphine equivalent dose and pain. It is not known if risk of depression varies as a function of the type of opioid prescribed. Methods: A retrospective cohort design was used to model onset of new depression diagnosis among 11462 Veterans Health Administration (VA) patients who were prescribed only codeine, only hydrocodone or only oxycodone for >30days. Patients were free of prevalent opioid use and depression at baseline (2000-2001). Follow-up was 2002-2012. Propensity scores and weighting were used to balance covariates across opioid type. Cox-proportional hazard models were computed, using weighted data and additional adjustment for morphine equivalent dose (MED), duration of use, and pain after opioid initiation, to estimate the risk of new depression diagnosis among patients prescribed only codeine, only oxycodone vs. those prescribed only hydrocodone. Results: After controlling for confounding, we observed that patients prescribed codeine, compared to hydrocodone, were significantly more likely to have a new depression diagnosis (HR=1.27; 95%CI: 1.12-1.43). Oxycodone was significantly associated with onset of new depression diagnosis when exposure was modeled as total days exposed in post-hoc analysis, but not when exposure was duration of incident period of use. Conclusions: Although codeine is a less potent opioid, after controlling for MED, chronic use of this agent is associated with nearly a 30% greater risk of depression compared to hydrocodone. Additional research is needed to determine the mechanisms for this association.

AB - Purpose: Longer duration of prescription opioid use is associated with risk of major depression after controlling for daily morphine equivalent dose and pain. It is not known if risk of depression varies as a function of the type of opioid prescribed. Methods: A retrospective cohort design was used to model onset of new depression diagnosis among 11462 Veterans Health Administration (VA) patients who were prescribed only codeine, only hydrocodone or only oxycodone for >30days. Patients were free of prevalent opioid use and depression at baseline (2000-2001). Follow-up was 2002-2012. Propensity scores and weighting were used to balance covariates across opioid type. Cox-proportional hazard models were computed, using weighted data and additional adjustment for morphine equivalent dose (MED), duration of use, and pain after opioid initiation, to estimate the risk of new depression diagnosis among patients prescribed only codeine, only oxycodone vs. those prescribed only hydrocodone. Results: After controlling for confounding, we observed that patients prescribed codeine, compared to hydrocodone, were significantly more likely to have a new depression diagnosis (HR=1.27; 95%CI: 1.12-1.43). Oxycodone was significantly associated with onset of new depression diagnosis when exposure was modeled as total days exposed in post-hoc analysis, but not when exposure was duration of incident period of use. Conclusions: Although codeine is a less potent opioid, after controlling for MED, chronic use of this agent is associated with nearly a 30% greater risk of depression compared to hydrocodone. Additional research is needed to determine the mechanisms for this association.

KW - Depression

KW - Epidemiology

KW - Opioids

KW - Pharmacoepidemiology

KW - Retrospective cohort

UR - http://www.scopus.com/inward/record.url?scp=84964780759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964780759&partnerID=8YFLogxK

U2 - 10.1002/pds.3999

DO - 10.1002/pds.3999

M3 - Article

VL - 25

SP - 560

EP - 568

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 5

ER -